clinical trial · NCT05171855
A Trial to Investigate Long Term Efficacy and Safety of Lonapegsomatropin in Adults With Growth Hormone Deficiency
Ascendis Pharma Endocrinology Division A/S·phase3·completed·n = 220
Adult Growth Hormone DeficiencyEndocrine System DiseasesHormone DeficiencyLonapegsomatropin
brief summary
This was a phase 3 open-label multicenter extension study designed to evaluate the long-term safety and efficacy of Lonapegsomatropin administered once-weekly. The study participants were adults (males and females) with confirmed growth hormone deficiency (GHD) having completed the treatment period in study TCH-306 (foresiGHt; NCT04615273).
started
Dec 16, 2021
primary completion
Dec 23, 2024
completion
Dec 23, 2024
last updated
Jan 9, 2026
official title
A Multicenter, Open-Label, Extension Trial to Investigate Long Term Efficacy and Safety of Lonapegsomatropin in Adults With Growth Hormone Deficiency
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol